ArticleMolecular neurobiology2026
Leukocytes Transcriptome Analysis of Genes Associated with Epilepsy Duration and Age of Onset.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Epilepsy is increasingly understood not as a fixed condition, but a dynamic and potentially progressive disorder. Beyond its primary impact on the brain, growing evidence indicates that epilepsy also exerts widespread systemic effects, influencing multiple physiological systems. Two temporal factors-the age at seizure onset and duration of epilepsy-could help understand if time with epilepsy shapes systemic molecular changes and in turn provide new insights into disease progression and therapeutic resistance. To identify systemic signatures associated with age of onset and epilepsy duration, we investigated the molecular correlates of them using leukocyte transcriptome. Differential expression analyses of short (≤ 20 years) vs. long (> 20 years) disease duration and childhood (≤ 12 years) vs. adolescent (> 12 years) onset-age revealed distinct leukocyte transcriptomics signatures. Gene expression changes related to disease duration were enriched for pathways involved in oxidative stress and disruptions in RNA/DNA regulatory processes. Epilepsy onset was linked to enrichment of protein demannosylation, deglycosylation and immune-related pathways, particularly those involving the MHC protein complex and antigen presentation. Spearman's correlation analyses uncovered genes whose expression correlated with age of onset and duration. Additionally, we found many differentially expressed genes located within the EJM1 locus on chromosome 6p21, the known major susceptibility locus for juvenile myoclonic epilepsy (JME). This finding suggests that co-regulated gene networks within this locus may act synergistically to influence neuroimmune interactions relevant to both the development and progression of epilepsy. The study suggests dynamic immune-related transcriptomic changes in epilepsy, which may warrant further investigation as potential biomarkers of disease onset and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.